Profile

Jane L. Burns, MD

Jane L. Burns, MD

Infectious Disease, Pediatrics-Inpatient, Cystic Fibrosis Research, Infectious Disease Research

On staff since October 1982

Academic Title: Professor, Pediatrics

Research Center: Center for Global Infectious Disease Research

"For a pediatrician, there is nothing better than to come to work every day in a facility that is totally geared toward children. From the giraffes who greet us at the entrance, to the phlebotomists, medical assistants, X-ray techs and nurses who work so well with kids, what we all do every day is support the lives of sick children and their families. What could be better?"

Jane L. Burns, MD: Professor of Pediatric Infectious Diseases. Dr. Burns primary area of research for many years has been cystic fibrosis (CF) microbiology, including antibiotic resistance and bacterial pathogenesis.

Dr. Burns' primary area of research for many years has been cystic fibrosis (CF) microbiology, including antibiotic resistance and bacterial pathogenesis. My laboratory has developed and tested novel methods of in vitro antibiotic susceptibility testing, including testing drug activity against bacteria grown in biofilms and examining drug bioactivity in the presence of CF sputum. She has worked in vitro and in vivo models of infection to examine bacterial pathogenesis including attachment, invasion and apoptosis. Her recent work has examined the phenotypic and genotypic adaptations of Pseudomonas aeruginosa, Burkholderia cenocepacia and Staphylococcus aureus organisms to growth within the CF airway.

Dr. Burns frequently collaborates with clinical and basic science CF researchers at Seattle Childrens Hospital and the University of Washington, providing both bacterial isolates and expertise with CF microbiology. In addition, she directs the Center for CF Microbiology at Seattle Childrens Hospital, which is a core laboratory for the CF Foundation Therapeutics Development Network.

Overview

Board Certification(s)

Pediatric Infectious Diseases
Pediatrics

Medical/Professional School

University of Washington, Seattle

Residency

Pediatrics, University of Washington, Seattle

Fellowship

Pediatric Infectious Disease, University of Washington, Seattle

Clinical Interests

Cystic fibrosis microbiology, bacterial antibiotic resistance, bone and joint infections

Research Description

Investigating the bacteria that cause cystic fibrosis
Cystic fibrosis (CF) is the most common life-shortening genetic illness in Caucasians, affecting approximately 30,000 children and adults in the U.S. alone. The abnormal CFTR gene impacts many organs, including the lungs, gastrointestinal tract and endocrine system. Chronic lung infections are the most common cause of morbidity and mortality in CF and our work is focused on the bacterial organisms that cause CF lung infections, including Pseudomonas aeruginosa, Burkholderia cepacia complex and Staphylococcus aureus. Because CF lung infections are polymicrobial, our work also addresses bacterial-bacterial interactions
P. aeruginosa is the most common organism causing lung infections in CF patients of all ages (although S. aureus is most common in children). The Burns lab's work on P. aeruginosa has primarily centered on early infections and how to eradicate them. Antibiotic resistance among P. aeruginosa isolates, including prevention, detection and treatment, has also been a longstanding area of research.
B. cepacia complex infections are relatively rare among individuals with CF, but can be deadly. Improving our understanding of the pathogenesis of these infections and identifying optimal treatment strategies are key to our ability to decrease the associated morbidity and mortality in CF patients harboring B. cepacia complex. As noted above, S. aureus is the organism most frequently isolated from children with CF. For many years, S. aureus was considered a "colonizer" that did not cause severe infections. However, recent data from our laboratory and others has identified increased morbidity in children infected with both methicillin resistant S. aureus (MRSA) and small colony variant S. aureus.
The Burns lab's current projects include investigation of the pathogenesis of B. cepacia complex in CF including the role of mucoidy in Burkholderia species and the contribution of hypermutability to specific bacterial phenotypes and clinical outcomes in B. cenocepacia infections in CF. In addition, the prevalence of small colony variant S. aureus and its impact on disease progression in children is being investigated. At the same time, we are developing new methods for antimicrobial susceptibility testing in these slow-growing variants with the goal of ultimately performing a large multicenter clinical trial.

Lab URL

http://www.seattlechildrens.org/research/global-infectious-disease-research/burns-lab/

Research Focus Area

Host: Pathogen Interaction

Awards and Honors

Award Name Award Description Awarded By Award Date
Best Doctor Best Doctors in America 2014 2014
Best Doctor Best Doctors in America 2013
Golden Stethoscope Award Seattle Metropolitan magazine 2008
Named one of Seattle’s “Top Doctors” Named one of Seattle’s “Top Doctors” in Seattle magazine and Seattle Metropolitan magazine 2008
Named one of Seattle’s “Top Doctors” Named one of Seattle’s “Top Doctors” in Seattle magazine 2007
Named one of Seattle’s “Top Doctors” Named one of Seattle’s “Top Doctors” in Seattle magazine and Seattle Metropolitan magazine 2003 - 2006
Frederick C. Moll Prize in Pediatrics 1978
March of Dimes Fellow 1976 - 1977
WAMI Fellow 1975
B.S., Magna cum laude in Biology
Phi Beta Kappa

Publications

  • Mayer-Hamblett N, Rosenfeld M, Gibson RL, Ramsey BW, Kulasekara HD, Retsch-Bogart GZ, Morgan W, Wolter DJ, Pope CE, Houston LS, Kulasekara BR, Khan U, Burns JL, Miller SI, Hoffman LR
    Pseudomonas aeruginosa in vitro Phenotypes Distinguish Cystic Fibrosis Infection Stages and Outcomes.
    American journal of respiratory and critical care medicine , 2014 June
  • Tullis DE, Burns JL, Retsch-Bogart GZ, Bresnik M, Henig NR, Lewis SA, Lipuma JJ
    Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: A placebo-controlled trial.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2014 May : 13(3)296-305
  • De Soyza A, Hall AJ, Mahenthiralingam E, Drevinek P, Kaca W, Drulis-Kawa Z, Stoitsova SR, Toth V, Coenye T, Zlosnik JE, Burns JL, Sá-Correia I, De Vos D, Pirnay JP, J Kidd T, Reid D, Manos J, Klockgether J, Wiehlmann L, Tümmler B, McClean S, Winstanley C, EU FP7 funded COST Action BM1003 Cell surface virulence determinants of cystic fibrosis pathogens
    Developing an international Pseudomonas aeruginosa reference panel.
    MicrobiologyOpen , 2013 Dec. : 2(6)1010-23
  • Burns JL, Rolain JM
    Culture-based diagnostic microbiology in cystic fibrosis: Can we simplify the complexity?
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2013 Oct.
  • Anstead M, Saiman L, Mayer-Hamblett N, Lands LC, Kloster M, Goss CH, Rose L, Burns JL, Marshall B, Ratjen F
    Pulmonary exacerbations in CF patients with early lung disease.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2013 Sept.
  • Wolter DJ, Emerson JC, McNamara S, Buccat AM, Qin X, Cochrane E, Houston LS, Rogers GB, Marsh P, Prehar K, Pope CE, Blackledge M, Déziel E, Bruce KD, Ramsey BW, Gibson RL, Burns JL, Hoffman LR
    Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America , 2013 Aug. : 57(3)384-91
  • Ruddy J, Emerson J, Moss R, Genatossio A, McNamara S, Burns JL, Anderson G, Rosenfeld M
    Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin.
    Journal of aerosol medicine and pulmonary drug delivery , 2013 Apr, : 26(2)69-75
  • Liu ZH, Xu Y, Duo LB, Liu Y, Xu ZZ, Burns JL, Liu GR, Yang BF, Liu SL
    Pseudomonas aeruginosa isolates of distinct sub-genotypes exhibit similar potential of antimicrobial resistance by drugs exposure.
    Antonie van Leeuwenhoek , 2013 Apr, : 103(4)797-807
  • Qin X, Zerr DM, McNutt MA, Berry JE, Burns JL, Kapur RP
    Pseudomonas aeruginosa syntrophy in chronically colonized airways of cystic fibrosis patients.
    Antimicrobial agents and chemotherapy , 2012 Nov. : 56(11)5971-81
  • Rowe SM, Borowitz DS, Burns JL, Clancy JP, Donaldson SH, Retsch-Bogart G, Sagel SD, Ramsey BW
    Progress in cystic fibrosis and the CF Therapeutics Development Network.
    Thorax , 2012 Oct. : 67(10)882-90
  • Rosenfeld M, Bernardo-Ocampo C, Emerson J, Genatossio A, Burns J, Gibson R
    Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2012 Sept. : 11(5)456-7
  • Saiman L, Mayer-Hamblett N, Anstead M, Lands LC, Kloster M, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F, AZ0004 Macrolide Study Team
    Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa.
    Pediatric pulmonology , 2012 July : 47(7)641-8
  • Burns JL, Emerson J, Kuypers J, Campbell AP, Gibson RL, McNamara S, Worrell K, Englund JA
    Respiratory viruses in children with cystic fibrosis: viral detection and clinical findings.
    Influenza and other respiratory viruses , 2012 May : 6(3)218-23
  • Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW, EPIC Investigators
    Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
    Pediatric pulmonology , 2012 Feb. : 47(2)125-34
  • Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW, Early Pseudomonas Infection Control (EPIC) Investigators
    Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Archives of pediatrics & adolescent medicine , 2011 Sept. : 165(9)847-56
  • Burns JL, Emerson J, Kuypers J, Campbell AP, Gibson RL, McNamara S, Worrell K, Englund JA
    Respiratory viruses in children with cystic fibrosis: viral detection and clinical findings.
    Influenza and other respiratory viruses , 2011 Sept.
  • Jane L. Burns, MD
    Evolution of Pseudomonas aeruginosa virulence in infected patients revealed in a Dictyostelium discoideum host model
    Clin Microbiol Infect , 2011 Sept. : 1415-20
  • Green N, Burns JL, Mayer-Hamblett N, Kloster M, Lands LC, Anstead M, Ratjen F, Saiman L
    Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis.
    Journal of clinical microbiology , 2011 July : 49(7)2772-3
  • Moskowitz SM, Emerson JC, McNamara S, Shell RD, Orenstein DM, Rosenbluth D, Katz MF, Ahrens R, Hornick D, Joseph PM, Gibson RL, Aitken ML, Benton WW, Burns JL
    Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection.
    Pediatric pulmonology , 2011 Feb. : 46(2)184-92
  • Young RL, Malcolm KC, Kret JE, Caceres SM, Poch KR, Nichols DP, Taylor-Cousar JL, Saavedra MT, Randell SH, Vasil ML, Burns JL, Moskowitz SM, Nick JA
    Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR.
    PloS one , 2011 : 6(9)e23637
  • Mulcahy LR, Burns JL, Lory S, Lewis K
    Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis.
    Journal of bacteriology , 2010 Dec. : 192(23)6191-9
  • Elliott D, Burns JL, Hoffman LR
    Exploratory study of the prevalence and clinical significance of tobramycin-mediated biofilm induction in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Antimicrobial agents and chemotherapy , 2010 July : 54(7)3024-6
  • Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F, AZ0004 Azithromycin Study Group
    Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
    JAMA : the journal of the American Medical Association , 2010 May : 303(17)1707-15
  • Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL
    Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.
    Pediatric pulmonology , 2010 Apr, : 45(4)363-70
  • King P, Lomovskaya O, Griffith DC, Burns JL, Dudley MN
    In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
    Antimicrobial agents and chemotherapy , 2010 Jan. : 54(1)143-8
  • Hoffman LR, Richardson AR, Houston LS, Kulasekara HD, Martens-Habbena W, Klausen M, Burns JL, Stahl DA, Hassett DJ, Fang FC, Miller SI
    Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airway.
    PLoS pathogens , 2010 Jan. : 6(1)e1000712
  • MacLeod DL, Barker LM, Sutherland JL, Moss SC, Gurgel JL, Kenney TF, Burns JL, Baker WR
    Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.
    The Journal of antimicrobial chemotherapy , 2009 Oct. : 64(4)829-36
  • Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, EPIC Study Group
    Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
    Contemporary clinical trials , 2009 May : 30(3)256-68
  • Hoffman LR, Kulasekara HD, Emerson J, Houston LS, Burns JL, Ramsey BW, Miller SI
    Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2009 Jan. : 8(1)66-70
  • Hoffman LR, Kulasekara HD, Emerson J, Houston LS, Burns JL, Ramsey BW, Miller SI
    Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2009 Jan. : 8(1)66-70
  • Hayden HS, Gillett W, Saenphimmachak C, Lim R, Zhou Y, Jacobs MA, Chang J, Rohmer L, D'Argenio DA, Palmieri A, Levy R, Haugen E, Wong GK, Brittnacher MJ, Burns JL, Miller SI, Olson MV, Kaul R
    Large-insert genome analysis technology detects structural variation in Pseudomonas aeruginosa clinical strains from cystic fibrosis patients.
    Genomics , 2008 June : 91(6)530-7
  • Hayden HS, Gillett W, Saenphimmachak C, Lim R, Zhou Y, Jacobs MA, Chang J, Rohmer L, D'Argenio DA, Palmieri A, Levy R, Haugen E, Wong GK, Brittnacher MJ, Burns JL, Miller SI, Olson MV, Kaul R
    Large-insert genome analysis technology detects structural variation in Pseudomonas aeruginosa clinical strains from cystic fibrosis patients.
    Genomics , 2008 June : 91(6)530-7
  • Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy K, Oermann C, Gibson RL, AZLI Phase II Study Group
    A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
    Pediatric pulmonology , 2008 Jan. : 43(1)47-58
  • Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy K, Oermann C, Gibson RL, AZLI Phase II Study Group
    A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
    Pediatric pulmonology , 2008 Jan. : 43(1)47-58
  • Ernst RK, Moskowitz SM, Emerson JC, Kraig GM, Adams KN, Harvey MD, Ramsey B, Speert DP, Burns JL, Miller SI
    Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.
    The Journal of infectious diseases , 2007 Oct. : 196(7)1088-92
  • Ernst RK, Moskowitz SM, Emerson JC, Kraig GM, Adams KN, Harvey MD, Ramsey B, Speert DP, Burns JL, Miller SI
    Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.
    The Journal of infectious diseases , 2007 Oct. : 196(7)1088-92
  • Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, Ramsey BW
    Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
    Pediatric pulmonology , 2007 July : 42(7)610-23
  • Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, Ramsey BW
    Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
    Pediatric pulmonology , 2007 July : 42(7)610-23
  • Nguyen D, Emond MJ, Mayer-Hamblett N, Saiman L, Marshall BC, Burns JL
    Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
    Pediatric pulmonology , 2007 June : 42(6)533-41
  • Cheung KJ Jr, Li G, Urban TA, Goldberg JB, Griffith A, Lu F, Burns JL
    Pilus-mediated epithelial cell death in response to infection with Burkholderia cenocepacia.
    Microbes and infection / Institut Pasteur , 2007 June : 9(7)829-37
  • Nguyen D, Emond MJ, Mayer-Hamblett N, Saiman L, Marshall BC, Burns JL
    Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
    Pediatric pulmonology , 2007 June : 42(6)533-41
  • Cheung KJ Jr, Li G, Urban TA, Goldberg JB, Griffith A, Lu F, Burns JL
    Pilus-mediated epithelial cell death in response to infection with Burkholderia cenocepacia.
    Microbes and infection / Institut Pasteur , 2007 June : 9(7)829-37
  • D'Argenio DA, Wu M, Hoffman LR, Kulasekara HD, Déziel E, Smith EE, Nguyen H, Ernst RK, Larson Freeman TJ, Spencer DH, Brittnacher M, Hayden HS, Selgrade S, Klausen M, Goodlett DR, Burns JL, Ramsey BW, Miller SI
    Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients.
    Molecular microbiology , 2007 Apr, : 64(2)512-33
  • Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW
    Association between pulmonary function and sputum biomarkers in cystic fibrosis.
    American journal of respiratory and critical care medicine , 2007 Apr, : 175(8)822-8
  • D'Argenio DA, Wu M, Hoffman LR, Kulasekara HD, Déziel E, Smith EE, Nguyen H, Ernst RK, Larson Freeman TJ, Spencer DH, Brittnacher M, Hayden HS, Selgrade S, Klausen M, Goodlett DR, Burns JL, Ramsey BW, Miller SI
    Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients.
    Molecular microbiology , 2007 Apr, : 64(2)512-33
  • Anderson SW, Stapp JR, Burns JL, Qin X
    Characterization of small-colony-variant Stenotrophomonas maltophilia isolated from the sputum specimens of five patients with cystic fibrosis.
    Journal of clinical microbiology , 2007 Feb. : 45(2)529-35
  • Wagner T, Burns JL
    Anti-inflammatory properties of macrolides.
    The Pediatric infectious disease journal , 2007 : : 75-6
  • Goss CH, Burns JL
    Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.
    Thorax , 2007 : : 360-7
  • Gibson RL, Retsch-Bogart GZ, Oermann C, Milla C, Pilewski J, Daines C, Ahrens R, Leon K, Cohen M, McNamara S, Callahan TL, Markus R, Burns JL
    Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis.
    Pediatric pulmonology , 2006 July : 41(7)656-65
  • Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM, Burns JL, Kaul R, Olson MV
    Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.
    Proceedings of the National Academy of Sciences of the United States of America , 2006 May : 103(22)8487-92
  • Yoon SS, Coakley R, Lau GW, Lymar SV, Gaston B, Karabulut AC, Hennigan RF, Hwang SH, Buettner G, Schurr MJ, Mortensen JE, Burns JL, Speert D, Boucher RC, Hassett DJ
    Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions.
    The Journal of clinical investigation , 2006 Feb. : 116(2)436-46
  • Chen Y, Vasil AI, Rehaume L, Mant CT, Burns JL, Vasil ML, Hancock RE, Hodges RS
    Comparison of biophysical and biologic properties of alpha-helical enantiomeric antimicrobial peptides.
    Chemical biology and drug design , 2006 Feb. : 67(2)162-73
  • Moskowitz SM, Foster JM, Emerson JC, Gibson RL, Burns JL
    Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection.
    The Journal of antimicrobial chemotherapy , 2005 Nov. : 56(5)879-86
  • Nair BM, Joachimiak LA, Chattopadhyay S, Montano I, Burns JL
    Conservation of a novel protein associated with an antibiotic efflux operon in Burkholderia cenocepacia.
    FEMS microbiology letters , 2005 Apr, : 245(2)337-44
  • Beckmann C, Brittnacher M, Ernst R, Mayer-Hamblett N, Miller SI, Burns JL
    Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infections.
    Infection and immunity , 2005 Jan. : 73(1)444-52
  • Johnson LN, Han JY, Moskowitz SM, Burns JL, Qin X, Englund JA
    Pandoraea bacteremia in a cystic fibrosis patient with associated systemic illness.
    The Pediatric infectious disease journal , 2004 Sept. : 23(9)881-2
  • Watson ME Jr, Burns JL, Smith AL
    Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum.
    Microbiology (Reading, England) , 2004 Sept. : 150(Pt 9)2947-58
  • Urban TA, Griffith A, Torok AM, Smolkin ME, Burns JL, Goldberg JB
    Contribution of Burkholderia cenocepacia flagella to infectivity and inflammation.
    Infection and immunity , 2004 Sept. : 72(9)5126-34
  • Moskowitz SM, Foster JM, Emerson J, Burns JL
    Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
    Journal of clinical microbiology , 2004 May : 42(5)1915-22
  • Nair BM, Cheung KJ Jr, Griffith A, Burns JL
    Salicylate induces an antibiotic efflux pump in Burkholderia cepacia complex genomovar III (B. cenocepacia).
    The Journal of clinical investigation , 2004 Feb. : 113(3)464-73
  • Ernst RK, D'Argenio DA, Ichikawa JK, Bangera MG, Selgrade S, Burns JL, Hiatt P, McCoy K, Brittnacher M, Kas A, Spencer DH, Olson MV, Ramsey BW, Lory S, Miller SI
    Genome mosaicism is conserved but not unique in Pseudomonas aeruginosa isolates from the airways of young children with cystic fibrosis.
    Environmental microbiology , 2003 Dec. : 5(12)1341-9
  • Ordoñez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML
    Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.
    American journal of respiratory and critical care medicine , 2003 Dec. : 168(12)1471-5
  • Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW 3rd, Macrolide Study Group
    Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
    JAMA : the journal of the American Medical Association , 2003 Oct. : 290(13)1749-56
  • Qin X, Emerson J, Stapp J, Stapp L, Abe P, Burns JL
    Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis.
    Journal of clinical microbiology , 2003 Sept. : 41(9)4312-7
  • Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL
    Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
    Chest , 2003 May : 123(5)1495-502
  • Zahariadis G, Levy MH, Burns JL
    Cepacia-like syndrome caused by Burkholderia multivorans.
    The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses , 2003 Mar. : 14(2)123-5
  • Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B, Cystic Fibrosis Therapeutics Development Network Study Group
    Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
    American journal of respiratory and critical care medicine , 2003 Mar. : 167(6)841-9
  • Zahariadis G, Levy MH, Burns JL
    Cepacia-like syndrome caused by Burkholderia multivorans.
    The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses , 2003 Mar. : 14(2)123-5
  • Spencer DH, Kas A, Smith EE, Raymond CK, Sims EH, Hastings M, Burns JL, Kaul R, Olson MV
    Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosa.
    Journal of bacteriology , 2003 Feb. : 185(4)1316-25
  • Jane L. Burns, MD
    Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosa
    J Bacteriol , 2003 Feb. : 1316-25
  • Saiman L, Burns JL, Larone D, Chen Y, Garber E, Whittier S
    Evaluation of MicroScan Autoscan for identification of Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Journal of clinical microbiology , 2003 Jan. : 41(1)492-4
  • Saiman L, Burns JL, Larone D, Chen Y, Garber E, Whittier S
    Evaluation of MicroScan Autoscan for identification of Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Journal of clinical microbiology , 2003 Jan. : 492-4
  • Park JR, Coughlin J, Hawkins D, Friedman DL, Burns JL, Pendergrass T
    Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
    Medical and pediatric oncology , 2003 : : 93-8
  • Tomich M, Griffith A, Herfst CA, Burns JL, Mohr CD
    Attenuated virulence of a Burkholderia cepacia type III secretion mutant in a murine model of infection.
    Infection and immunity , 2003 : : 1405-15
  • Aitken ML, Greene KE, Tonelli MR, Burns JL, Emerson JC, Goss CH, Gibson RL
    Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis.
    Chest , 2003 : : 792-9
  • Gibson RL, Burns JL, Ramsey BW
    Pathophysiology and management of pulmonary infections in cystic fibrosis.
    American journal of respiratory and critical care medicine , 2003 : : 918-51
  • Cieri MV, Mayer-Hamblett N, Griffith A, Burns JL
    Correlation between an in vitro invasion assay and a murine model of Burkholderia cepacia lung infection.
    Infection and immunity , 2002 Mar. : 70(3)1081-6
  • Cieri MV, Mayer-Hamblett N, Griffith A, Burns JL
    Correlation between an in vitro invasion assay and a murine model of Burkholderia cepacia lung infection.
    Infection and immunity , 2002 Mar. : 1081-6
  • Van Dalfsen JM, Stapp JR, Phelps C, Stewart P, Burns JL
    Comparison of two culture methods for detection of tobramycin-resistant gram-negative organisms in the sputum of patients with cystic fibrosis.
    Journal of clinical microbiology , 2002 : 40: 26-30
  • Brown JC, Burns JL, Cummings P
    Ampicillin use in infant fever: a systematic review.
    Archives of pediatrics and adolescent medicine , 2002 Jan. : 27-32
  • Liu L, Coenye T, Burns JL, Whitby PW, Stull TL, LiPuma JJ
    Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients.
    Journal of clinical microbiology , 2002 : : 1210-1213
  • Burns JL
    Emergence of new pathogens in CF: the devil we know or the devil we don't know?
    The Journal of pediatrics , 2002 : : 283-4
  • Graff GR, Burns JL
    Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis.
    Chest , 2002 : 121: 1754-1760
  • Watkins SL, Alexander SR, Brewer ED, Hesley TM, West DJ, Chan IS, Mendelman P, Bailey SM, Burns JL, Hogg RJ
    Response to recombinant hepatitis B vaccine in children and adolescents with chronic renal failure.
    American journal of kidney diseases : the official journal of the National Kidney Foundation , 2002 : 40: 365-372
  • Nair B, Stapp J, Stapp L, Bugni L, Van Dalfsen J, Burns JL
    Utility of gram staining for evaluation of the quality of cystic fibrosis sputum samples.
    Journal of clinical microbiology , 2002 : : 2791-2794

Presentations

Presentations Title Event Location Date
Newest evidence for management of pediatric urinary tract infections North Pacific Pediatric Society 183rd Scientific Conference Coeur d’Alene, ID Aug. 2011
Understanding the clinical microbiology lab NACFC Baltimore, MD Oct. 2010
Small colony variants in CF: Watch out for the little guys NW ASM Branch Meeting Seattle, WA Oct. 2010
The red queen: A history of infectious disease North Pacific Pediatric Society 180th Scientific Conference Seattle, WA March 2010
Unique problems in cystic fibrosis microbiology Northwest Medical Laboratory Symposium (NWMLS) Seattle, WA Oct. 1, 2009
Diagnosis and management of cystic fibrosis airway infections Grand Rounds, Hospital for Sick Children Toronto, Ontario, Canada Sept. 1, 2009
Molecular diagnostics in cystic fibrosis microbiology Symposium on Respiratory Infections, Novel Research Exploring Diagnosis and Management - SickKids Research Institute Toronto, Ontario, Canada Sept. 1, 2009
CF airway infections - Opponent for Ph.D. dissertation, Elin Nilsson Uppsala Universitet Stockholm, Sweden May 1, 2009
Antibiotic susceptibility testing in CF Uppsala Universitet Stockholm, Sweden May 1, 2009
Pathogenesis of cystic fibrosis lung infections, important pathogens Karolinska Universitetssjukhuset CF Regionstudiedag Stockholm, Sweden May 1, 2009
Hypermutability of B. cenocepacia in CF International Burkholderia cepacia Working Group (IBCWG) Toronto, Canada April 1, 2009
Challenging the paradigm: novel susceptibility testing methods for CF North Killarney National Cystic Fibrosis Meeting Killarney, Ireland Jan. 2, 2009

Research Funding

Grant Title Grantor Amount Award Date
Prevalence and Clinical Significance of S. aureus small-colony variants - HOFFMA14A0 (PI: Burns and Hoffman) Cystic Fibrosis Foundation Therapeutics $109,481 Burns annual direct costs April 1, 2014 - March 31, 2017
Long Term Outcomes after Eradication of Pseudomonas aeruginosa among Children Enrolled in the EPIC Clinical Trial - #CTBM100CUSNC01T (PI: Hamblett) Novartis $34,426 annual direct costs Dec. 15, 2013 - Dec. 15, 2015
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with Cystic Fibrosis - UM1 HL119073 (PI: Goss) $55,495 Burns' annual direct costs Sept. 1, 2013 - June 30, 2016
A Phase 2, Randomized, Double Blind, Placebo-Controlled, Repeat-Dose Study of KB001 A in Subjects with Cystic Fibrosis Infected with Pseudomonas aeruginosa KaloBios Pharmaceuticals, Inc. $45,032 total direct costs Oct. 10, 2012 - Oct. 9, 2014
Lab Services - Grifols Protocol# T6005-201 Grifols Therapeutics, Inc. April 10, 2012 - April 10, 2014
Persistent MRSA Eradication Protocol - #PMEP11K1 (PI: Dasenbrook) CFFT $37,240 subcontract annual direct costs Jan. 1, 2012 - Dec. 31, 2014
Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis - P30 DK089507 (PI: Ramsey & Greenberg) NIH $25,749 Burns' annual direct costs July 6, 2010 - May 31, 2015
Safety and efficacy of aztreonam Gilead Sciences Jan. 12, 2010 - Jan. 12, 2015
Pseudomonas aeruginosa adaptation during early cystic fibrosis infection and treatment NIH $ Sept. 11, 2009 - July 31, 2014
Translational Therapeutics Development Center - #GIBSON09YO (PI: Gibson) Cystic Fibrosis Foundation Therapeutics $166,400 annual direct costs April 1, 2004 - Dec. 31, 2014
Therapeutics Development Network Coordinating Center (CFFT Infrastructure 2014-2015) (PI: Ramsey) CFFT $11,443 Burns' annual direct costs April 1, 2004 - March 31, 2015
Therapeutic Development Center Microbiology Core Laboratory - #BURNS03Y3 Cystic Fibrosis Foundation Therapeutics $112,315 annual direct costs April 1, 2003 - Dec. 31, 2014